Current status of dyslipidemia control in patients with type 1 diabetes mellitus in Slovakia

Czech version

Authors: Jozef Lacka ¹; Petra Ištokovičová ²; Martin Jankovský ³; Peter Jackuliak ³; Elena Tibenská ⁴
Authors‘ workplace: JAL, s. r. o., Trnava ¹; Inštitút zdravotných analýz (IZA) MZ SR, Bratislava ²; V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava ³; Medirex group academy n. o., Nitra ⁴
Published in: Forum Diab 2025; 14(2): 90-96
Category: Original Article

Overview

Introduction: Patients with type 1 diabetes mellitus (T1DM) are at high cardiovascular risk, with dyslipidemia being a key modifiable factor. In Slovakia, systematic data on achieving LDL targets according to the 2019 ESC/EAS and 2025 ADA guidelines are lacking. Methods: This retrospective analysis included 10,290 tests of lipid profiles patients with T1DM examined in Medirex laboratories between 2019 and 2023. Lipid profiles and HbA_1c were evaluated; all data were anonymized, and nonparametric statistical methods were applied. The evaluated data cover both the pre-pandemic period (2019) and the time during the COVID-19 pandemic (2020–2023). Results: The overall mean of the median laboratory values of the lipid profile parameters in patients with T1DM was: total cholesterol 4.62 mmol/l, triglycerides 1.18 mmol/l, HDL-C 1.44 mmol/l, and LDL-C 2.88 mmol/l. The median LDL-C did not change significantly. During the observed period, most results were in the range of 1.8–3.5 mmol/l (65–70 %). Only 7–9 % reached < 1.8 mmol/l and 1.9–2.7 % < 1.4 mmol/l, whereas 20–28 % had >3.5 mmol/l. Due to multiple analyzed years and variability, a range is reported. Conclusion: The majority of T1DM patients in Slovakia do not achieve recommended LDL targets, and outcomes are worse than in international registries. Low prescription rates of LLT, therapeutic inertia, and poor patient adherence require systematic improvement of lipid control, including combined therapy and national monitoring.

Sources

Rawshani A, Sattar N, Franzén S et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet 2018; 392(10146): 477–486. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)31506-X>.

[American Diabetes Association Professional Practice Committee]. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes –⁠ 2025. Diabetes Care 2025; 48(Suppl. 1): S207–S230. Dostupné z DOI: <http://dx.doi.org/10.2337/dc25-S010>.

[ADA Professional Practice Committee]. Lipid Management in Diabetes. ADA Standards of Care 2025 –⁠ Knowledge Document. 2025. Dostupné z WWW: <https://wellaheadla.com/wp-content/uploads/2025/02/Standards-of-Care-in-Diabetes-2025.pdf>.

Mach F, Baigent C, Catapano AL et al. [ESC Scientific Document Group]. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111–188. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz455>.

Šebová M et al. Reference values of serum lipids in the Slovak pediatric population. Cent Eur J Public Health 2015; 23(1): 30–34.

Mokáň M et al. Epidemiológia diabetu na Slovensku. Vnitř Lék 2019; 65(7–8): 463–468.

Rawshani A, Rawshani A, Franzén S et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2018; 379(7): 633–644. Dostupné z DOI: <https://doi: 10.1056/NEJMoa1800256>.

Soedamah-Muthu SS, Chaturvedi N, Toeller M et al. [EURODIAB Prospective Complications Study Group]. Risk factors for coronary heart disease in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2004; 27(2): 530–537. Dostupné z DOI: <https://doi: 10.2337/diacare.27.2.530>.

Holl RW, et al. Lipid screening and statin therapy in children and adolescents with type 1 diabetes: data from the DPV registry. Pediatr Diabetes 2017; 18(5): 320–327.

Reiner Ž et al. Lipid control in Europe: gaps in cardiovascular risk management. Eur J Prev Cardiol 2021; 28(12): 1320–1330.

[DCCT/EDIC Research Group]. Lipoprotein subclasses in type 1 diabetes and progression of nephropathy. Diabetes Care 2011; 34(4): 955–961.

Miller KM, Foster NC, Beck RW et al. Current state of type 1 diabetes treatment in the U.S.: T1D Exchange clinic registry. Diabetes Care 2015; 38(6): 971–978. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15–0078>.

Costacou T, Orchard TJ. Dyslipidemia and its treatment in type 1 diabetes: an update. Curr Diab Rep 2018; 18(10): 83.

Breuker C, Macioce V, Lasse A et al. Attainment of LDL-cholesterol target in high cardiovascular risk type 1 diabetic French people. Diabetes Metab 2024; 50(6): 101568. Dostupné z DOI: <https://10.1016/j.diabet.2024.101568>.

Cosson E, et al. Sex inequalities in cardiovascular risk factors and their treatment in patients with type 1 diabetes: data from the DPV registry. Diabetologia 2024; 67(6): 993–1005. PMC: 11406774.

Banach M, Surma S, Toth PP et al. 2023: The year in cardiovascular disease –⁠ the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?. Arch Med Sci 2023; 19(6): 1602–1615. Dostupné z DOI: <https://doi.org/10.5114/aoms/174743>.

Rawshani A, Aidin Rawshani 1, Araz Rawshani 1, Stefan Franzén 1,et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 1 diabetes. N Engl J Med 2018;379(7):233–244.

[Swedish NDR (The Swedish National Diabetes Register)]. Diabetologia 2025; online ahead of print.